Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Biotechnology

Healthcare
$298.71 +1.10%

+$2.89 today

Market cap
$5.98B
Beta
1.04
P/E (TTM)
34.4
EPS (TTM)
$7.72
52W Low $110.00High $268.43

Volume 0.38M

Average 0.22M

LGND Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 95.0%

Gross margin was 95.0% in Q2 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 98.6%, up 10.9 pp year over year. Over 3 fiscal years it widened by 24.5 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
95.0%-1.0 pp QoQ
Last fiscal yearDec 2025
97.5%+4.2 pp YoY
LTMJun 2026
98.6%+10.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.1 pp——
1 year+4.2 pp——
3 years+24.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.5%
Year-over-year change
+4.2pp

Gross Margin vs competitors

How LGND compares with its peers on the latest reported figures

  • LGND's LTM Jun 2026 gross margin of 98.6% is the highest of the 10 companies compared; the peer median is 76.3%.
  • Its year-over-year change of +10.9 pp is the highest of 9, against a peer median of +0.5 pp.
  • Over three fiscal years its change of +24.5 pp compares with a peer median of -1.1 pp.
LGND Competitors Peer median
Gross Margin for LGND and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202698.6% +10.9 pp+24.5 pp
EXELExelixis, Inc.LTM Jul 202696.5% -0.1 pp-0.0 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
INCYIncyte CorporationLTM Jun 202692.6% -0.3 pp-1.1 pp
ABBVAbbVie Inc.LTM Sep 202676.3% +6.5 pp+0.2 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202670.2% -0.1 pp-7.0 pp
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 202623.5% -73.5 pp+0.3 pp
Peer median (excluding LGND) 76.3%+0.5 pp-1.1 pp

Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue241.54M196.25M131.31M167.13M268.09M
Cost of Revenue62.18M52.83M35.05M11.07M6.59M
Gross Profit179.37M143.42M96.27M156.06M261.5M
Gross Margin74.3%73.1%73.3%93.4%97.5%
Research & Development32.11M36.08M24.54M21.43M81.18M
Selling, General & Admin46.79M70.06M52.79M78.65M92.45M
Operating Expenses75.52M140.38M84.32M178.67M214.3M
Depreciation & Amortization50.95M43.39M36.52M35.24M33.78M
EBITDA142.77M81.2M100.84M40.79M192.74M
EBITDA Margin59.1%41.4%76.8%24.4%71.9%
Operating Income103.85M3.04M11.94M(22.61M)47.2M
Operating Margin43.0%1.5%9.1%-13.5%17.6%
Interest Income886K2.05M7.71M8.06M13.66M
Interest Expense19.62M1.8M656K3.04M4.72M
Other Income / Expenses(31.65M)32.97M51.72M25.12M111.76M
Income Before Tax72.21M36.01M63.66M2.52M158.96M
Pre-Tax Margin29.9%18.4%48.5%1.5%59.3%
Income Tax Expense(4.15M)41.23M9.84M6.55M34.51M
Net Income57.14M(33.36M)52.15M(4.03M)124.45M
Net Margin23.7%-17.0%39.7%-2.4%46.4%
EPS (Basic)3.46(1.98)3.02(0.22)6.44
EPS (Diluted)3.34(1.98)2.94(0.22)6.13
Weighted Avg Shares16.63M16.87M17.3M18.29M19.34M
Weighted Avg Shares (Diluted)17.25M16.87M17.76M18.29M20.29M

Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Intrinsic Alpha fair value

Locked

Current Price

$298.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.